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Intravascular lithotripsy (IVL) has been shown to be safe and effective for calcium modification in nonocclusive coronary artery
disease (CAD), but there are only case reports of its use in calcified chronic total occlusions (CTO). We report data from an
international multicenter registry of IVL use during CTO percutaneous coronary intervention (PCI) and provide provisional data
regarding its efficacy and safety. During the study period, IVL was used in 55 of 1053 (5.2%) CTO PCI procedures. IVL was used
within the occluded segment after successful CTO crossing in 53 procedures and during incomplete CTO crossing in 2 cases. )e
mean J-CTO score was 3.1. CTO PCI technical and procedural success was achieved in 53 (96%) and 51 (93%) cases. Six patients
had a procedural complication, with 3 main vessel perforations (5%). Two had covered stent implantation, one required
pericardiocentesis, and one was managed conservatively. All had combination therapy with another calcium modification device.
Two patients had a procedural myocardial infarction (PMI) (4%), and two others had a major adverse cardiovascular event
(MACE) (4%) at a median follow-up of 13 (4–21) months. IVL can effectively facilitate calcium modification during CTO PCI.
More data are required to establish the efficacy and safety of IVL and other calciummodification devices when used extraplaque or
in combination during CTO PCI.
1. Introduction
Calcification within a chronic total occlusion (CTO) is an
independent predictor of percutaneous coronary interven-
tion (PCI) failure, prolonged procedure duration, subopti-
mal stent expansion, and complications and thus is a key
characteristic in CTO complexity scores [1–4]. Calcium is
most commonly located at the proximal cap and also fre-
quently present within the occlusive segment and at the
distal cap, particularly in postbypass native vessel occlusions
where it is most prevalent [5].
CTOs can be crossed by luminal tracking (“intraplaque”)
or by dissecting around the occlusion and through the less-
resistant subintimal space (“extraplaque”). )is can be done
antegradely (antegrade wiring (AW) or antegrade dissection
re-entry (ADR)) or retrogradely (retrograde wiring (RW) or
retrograde dissection re-entry (RDR)). Calcium modifica-
tion is required more often if the course is intraplaque.
While the morphology of plaque calcium can be concentric,
eccentric, or nodular, extraplaque tracking and displacement
of the plaque and lumen can result in the formation of a
calcified “pseudonodule” (Figure 1).
Calcium modification is frequently performed during
CTO PCI using scoring (SB), cutting (CB), and high-
pressure (OPN) balloons or rotational (RA), orbital or laser
atherectomy, although there are limited published data on
Hindawi
Journal of Interventional Cardiology
Volume 2021, Article ID 9958035, 6 pages
https://doi.org/10.1155/2021/9958035
the efficacy and safety of these devices in this patient
population [6, 7]. While the more recently available
Shockwave ™ intravascular lithotripsy (IVL) balloon has
been demonstrated to be safe and effective in nonocclusive
CAD [8–12], there are only few case reports of its use during
CTO PCI [13, 14].
We describe the initial experience of using IVL during
CTO PCI and provide provisional data regarding its efficacy
and safety.
2. Materials and Methods
We retrospectively identified patients treated with IVL
within the occluded segment during CTO PCI at 5 high-
volume centers in the UK and Norway.
We describe the patient demographics, clinical presen-
tation, CTO characteristics, procedural strategy, and calcium
modification techniques. )e procedural angiograms and
reports were systematically reviewed and adjudicated by two
members of the CTO team at each site.
Procedural outcomes, complications, and inhospital
major adverse cardiovascular event (MACE) rates are re-
ported. Long-term MACE rates were determined from
electronic databases. Definitions were applied according to
the CTO Academic Research Consortium (CTO ARC) [15].
All patients gave consent for use of their anonymized data.
3. Results
During the study period, 1053 patients had CTO PCI, with
IVL used for calcium modification within the occluded
segment in 55 patients (5,2%). Patient demographics, clinical
presentation, and CTO characteristics are described in Ta-
ble 1. )e CTOs were high complexity with 36% having
previous coronary artery bypass grafting (CABG), 20%
having a previous failed CTO PCI attempt, and with a mean
J-CTO score of 3.1.
Procedural setup, final strategy, and calcium modifica-
tion techniques are described in Table 2. Biradial or radial-
femoral dual access was used in 80% of cases. )e pro-
portions of final successful crossing strategy were consistent
with contemporary CTO registries [16, 17]. Intravascular
imaging was used in almost 90% of cases.
IVL was used after successful CTO crossing and prior to
stenting in 53 cases and after incomplete CTO crossing
during a CTOmodification procedure in 2 cases. It was used
extraplaque in 35% of patients. )e decision to use IVL was
made by the operator after assessing plaque modification to
be inadequate after initial treatment with a noncompliant
(NCB), scoring (SB), cutting (CB), high-pressure balloon
(OPN), or rotational atherectomy (RA). Inadequate plaque
modification was determined either angiographically by
observing balloon under expansion, as is routine practice, or
by intravascular imaging. Lesion pretreatment was per-
formed using an NCB in 96% of cases and an additional
calciummodification device (SB, CB, OPN, or RA) in 42% of
cases prior to IVL use (Figure 2). Additional calcium
modification devices were used after IVL in 22% of cases
(Figure 2). In total, combination therapy of IVLwith another
calciummodification device was required in 53% of patients.
Figure 3 illustrates a case where IVL was used following RA,
demonstrating the initial underexpanded IVL balloon
during delivery of the first 10 pulses of therapy and IVUS
confirmation of adequate stent expansion.
CTO PCI technical and procedural success were
achieved in 53 (96%) and 51 (93%) patients, respectively. Of
the eleven cases that were reattempts, 5 had a CTO modi-
fication procedure at the time of the first attempt, with IVL
used in 2 patients at the proximal cap and extraplaque. Both
patients subsequently had successful staged CTO PCI
completion (1 ADR and 1 RDR). Drug eluting balloons were
used in almost 1 in 5 cases, either for instent restenosis or to
treat distal disease.
)ere were three (5%) Ellis grade 3 main vessel perfo-
rations. One following IVUS confirmed intraplaque crossing
of a tortuous right coronary artery (RCA), with RA followed
by IVL, resulting in tamponade, pericardiocentesis, and
covered stent implantation. )e second after IVUS con-
firmed extraplaque crossing of a left anterior descending
(LAD) artery, modified with an SB and IVL, treated with a
covered stent. )e third following IVUS confirmed
extraplaque crossing of an RCA, with IVL (10 pulses of
therapy at the perforation site) followed by CB and stenting,
resulting in an atrioventricular groove hematoma managed
conservatively. )ere was 1 femoral access site bleed re-
quiring blood transfusion, 1 heart block requiring pace-
maker implantation, and 1 septal perforation requiring
coiling.
Two patients had a procedural myocardial infarction
(PMI) (4%). Two other patients had target lesion revascu-
larization (TLR) due to instent restenosis (ISR). )ere were
no other MACE at a median follow-up of 13 (4–21) months.
4. Discussion
)is is the first reported cohort of patients treated with IVL
for calcium modification during CTO PCI. In almost all
cases, IVL was used after CTO crossing, intraplaque in two-
thirds, and extraplaque in one-third of patients. In over 50%
of cases IVL was used in combination with another device,
most commonly after incomplete calcium modification with
the first device, but in 22% of cases, additional calcium
modification was needed after IVL. Of the 3 main vessel
perforations, all occurred where IVL was used in combi-
nation with another device, and in 2 cases extraplaque.
Following intraplaque crossing and predilatation, we
would anticipate that the efficacy and safety of IVL would be
the same as in nonocclusive disease. While the efficiency of
its use is a potential advantage during prolonged CTO PCI
procedures, atherectomy may be required for balloon un-
crossable lesions or to treat extensive segments of calcific
disease.
When dissection re-entry is used for CTO crossing, the
technique itself results in plaque and luminal displacement
with associated calcium “modification.” )is can result in
the formation of a “calcified pseudonodule” (Figure 1), with
further modification and stenting occurring extraplaque.
Inadequate modification of a calcified nodule results in
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eccentric stent expansion, and while debulking with athe-
rectomy is thought to be most effective in treating intra-
plaque nodules, there are limited data on its efficacy and
safety extraplaque [6, 7]. Indeed, without favorable wire-
bias, especially when using small burrs, modification will be









Figure 1: Calciummorphologies (concentric: smooth surfaced with reverberations consistent with thin calcium; eccentric: irregular surface
with no reverberation consistent with thick calcium; nodule: luminal protrusion with irregular leading edge; pseudonodule: subintimal
space expansion with displacement of calcified plaque and lumen).





Stable angina 43 (78%)
Acute coronary syndrome 11 (20%)
Asymptomatic ischemia 2 (3.6%)
Prior CABG 20 (36%)












>1 vessel treated 2 (3.5%)
CTO characteristics
Calcification 55 (100%)
Ambiguous proximal cap 21 (38%)
Length >20mm 35 (63.6%)
Tortuosity 24 (43.6%)
Ambiguous distal cap 26 (47.3%)
Instent occlusion 8 (14.5%)
Reattempt 11 (20%)
Modification procedure at 1st attempt 5 (9.1%)
J-CTO score (0–5)(mean) 3.1
[CABG� coronary artery bypass grafting; PCI� percutaneous coronary intervention; eGFR� estimated glomerular filtration rate; LVEF� left ventricular
ejection fraction; LAD� left anterior descending artery; RCA� right coronary artery; CX� circumflex artery; LMS� left main stem; J-CTO� Japanese-CTO
score].
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and IVL are frequently used to treat nodular calcium in
nonocclusive disease, their efficacy and safety has not been
described. Furthermore, the efficacy and safety of all the
calciummodification devices is uncertain in the treatment of
extraplaque pseudonodular calcium.
IVL could potentially be used to facilitate CTO
crossing, specifically for balloon-assisted subintimal entry
(BASE) at a calcified proximal cap, or in connecting
antegrade and retrograde spaces during RDR (14). In
addition, as described in two of our cases, it may have a
role during modification procedures for complex calcified
CTOs [15].
)e key limitation of this study is that it is a retrospective,
observational cohort. In addition, it should be noted that IVL
was used after CTO crossing in almost all cases and thus
introduces bias to procedural success rates. A period of novel
technology adoption and impact of incremental device cost will
have introduced some case selection bias, increasing the
proportion of cases where an additional calcium modification
device was used before IVL, where with improved access and
more experience, IVL could be the first choice device when
initial treatment with NCB has failed. While intravascular
imaging was used in 90% of the procedures, quantitative data
was not available for analysis.
Table 2: Procedural data.
N� 55
Access site




Dual injection angiography 46 (83.6%)
















IVL balloons (mean number/case) 1.2
Number of pulses (mean) 60
Proximal cap 51 (92.7%)
CTO body 51 (92.7%)
Extraplaque 19 (34.5%)
Guide extension delivery 28 (50.1%)
Balloon burst 7 (12.7%)








Number of stents (mean) 2.5
Mean stent length (mm) 83
DEB 10 (18%)
AW� antegrade wiring; RDR� retrograde dissection re-entry; ADR� antegrade dissection re-entry; RW� retrograde wiring; IVUS� intravascular ultra-
sound; OCT�optical coherence tomography; IVL� intravascular lithotripsy; NCB�noncompliant balloon; SB� scoring balloon; CB� cutting balloon;
OPN� high-pressure balloon; RA� rotational atherectomy; DEB� drug eluting balloon.
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(a) (b) (c) (d)
(e) (f ) (g)
Figure 3: Calcium modification of mid-RCA CTO with RA and IVL. (a) Angiographic severe calcification mid-RCA; (b) RA; (c) IVUS
confirmed intraplaque crossing with concentric calcium; (d) IVL with dogbone; (e) “Shocktopics” on EKG; (f ) IVUS confirmed stent























Figure 2: IVL use in combination therapy. SB� scoring balloon; CB� cutting balloon; OPN� high pressure balloon; RA� rotational
atherectomy; IVL� intravascular lithotripsy.
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5. Conclusion
IVL can be used effectively for calcium modification during
CTO PCI. More data are required to establish the efficacy
and safety of IVL and other calcium modification devices
during CTO PCI, especially when used extraplaque or as
combination therapy.
Data Availability
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